Jaguar Health to Reveal Key Updates on Rare Intestinal Disease Treatments
San Francisco, Friday, 12 June 2026.
Fresh off securing $42 million in new financing, Jaguar Health will present crucial updates on its pediatric rare intestinal disease treatments to investors on June 24, 2026.
Strategic Capital Influx and Structural Mechanics
On June 9, 2026, San Francisco-based Jaguar Health, Inc. (NASDAQ: JAGX) finalized a critical common stock equity line of credit (ELOC) agreement with an institutional investor [3][5]. This financing vehicle permits the company to sell up to $40 million of its common stock, providing substantial liquidity to fund general corporate operations and advance its clinical pipeline [3][5]. Concurrently, the pharmaceutical company closed a private placement, issuing 240 shares of Series P Non-Convertible Preferred Stock at a stated value of $10,000 per share, raising an additional $2 million [3]. The Series P shares carry an 8% annual dividend, payable quarterly in either cash or common stock [3].
Financial Fundamentals and Recent Performance
This capital infusion arrives on the heels of a transformative first quarter for the commercial-stage pharmaceutical entity [2][4]. For Q1 2026, Jaguar Health reported revenues of $20.27 million and a gross profit of $19.11 million [4]. This represents a staggering revenue expansion of 525.617 percent compared to the $3.24 million recorded in the fourth quarter of 2025 [4]. Moreover, the company’s cash position improved significantly, growing from just $968,000 at the end of 2025 to $7.28 million by the close of Q1 2026 [4].
Pipeline Milestones and Market Opportunities
The newly secured funds are expected to directly support the clinical progression of crofelemer, Jaguar’s flagship plant-derived prescription compound [1][2]. On June 12, 2026, the company announced that founder and CEO Lisa Conte will outline updates on the crofelemer development program at the Life Sciences Virtual Investor Forum, scheduled for 1:00 PM Eastern on June 24, 2026 [1]. This virtual presentation will run concurrently with the Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting, held from June 24 to June 27, 2026, where Jaguar will deliver two targeted presentations on crofelemer’s efficacy in pediatric patients suffering from microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) [1].
Navigating Regulatory Horizons
Looking ahead, Jaguar Health has outlined an aggressive regulatory timeline to expand crofelemer’s applications [2]. Following clinically meaningful subgroup benefits observed in the Phase 3 OnTarget trial, the company is targeting New Drug Application (NDA) filings by the end of December 2026 for crofelemer as a preventative treatment for cancer therapy-related diarrhea (CTD) [2]. The chemotherapy-induced diarrhea market across seven major global markets is projected to grow from approximately $80 million in 2023 to $164.6 million by 2035 [2]. As the June 24 presentations approach, healthcare investors will be closely monitoring how Jaguar Health plans to leverage its recent financing package to transition these clinical milestones into sustainable commercial success [1][3].